Egoropal

GIF decision: Marketing suspension

What does this decision mean?

  • Wstrzymanie w obrocie — The product has been temporarily suspended from circulation — sales are paused pending clarification, but it is not a full market recall.

A routine FDA inspection revealed serious deficiencies in aseptic manufacturing processes; the assessed risk to product quality and patient safety for aseptically filled batches on the market is high. The product is a parenteral solution for injection. Potential effects: infections after parenteral administration, severe complications, lack of treatment safety.

Download the app and stay informed

Get instant notifications about recalled products and protect your family.

Egoropal
Risk Level
Critical
Manufacturer
Egis Pharmaceuticals PLC z siedzibą w Budapeszcie, Węgry
Batch Number
4400718, 4500766, 4501274, 4400293, 4400851, 4500598, 4500832, 4500892, 4501060, 4501376
Notice Date
23.12.2025
View official statement

Related

Other Notices